Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RD03/2016
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 27, 2024
Lead Product(s) : RD03/2016
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Hyaluronate
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : I-MED
Deal Size : Undisclosed
Deal Type : Partnership
Details : NTC and I-MED Pharma’s successful collaboration to bring I-DEFENSE® innovative ophthalmic ointment first to Canada and now to the U.S.A. is a testament to the dedication of both companies to advancing the science of dry eye.
Product Name : I-Defense
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 15, 2021
Lead Product(s) : Sodium Hyaluronate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : I-MED
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : NTC015
Therapeutic Area : Undisclosed
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 18, 2021
Lead Product(s) : NTC015
Therapeutic Area : Undisclosed
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Biovaginil
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
December 21, 2020
Lead Product(s) : Biovaginil
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levofloxacin,Dexamethasone
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Taro Pharmaceutical Industries
Deal Size : Undisclosed
Deal Type : Licensing Agreement
NTC Grants License and Distribution Rights in Israel to Taro Pharmaceutical Industries
Details : NTC Srl has granted exclusive license and distribution rights to one of its R&D products to Taro Pharmaceutical. The product combines a quinolone antibiotic with an anti-inflammatory steroid in eye drops intended to provide an appropriate treatment for p...
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Undisclosed
June 17, 2020
Lead Product(s) : Levofloxacin,Dexamethasone
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Taro Pharmaceutical Industries
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Levofloxacin
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 14, 2018
Lead Product(s) : Levofloxacin
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levofloxacin
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 14, 2018
Lead Product(s) : Levofloxacin
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lertal
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
December 07, 2017
Lead Product(s) : Lertal
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Hyaluronate Acid
Therapeutic Area : Ophthalmology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
October 04, 2017
Lead Product(s) : Sodium Hyaluronate Acid
Therapeutic Area : Ophthalmology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable